www.teijin.co.jp/news/2023/05/31/20230531_01.pdf

Latest saved version

帝人株式会社の子会社設立に関するお知らせ

This is the newest public snapshot for this URL and the best place to start reviewing the page.

Source URL

https://www.teijin.co.jp/news/2023/05/31/20230531_01.pdf

About this page

This document announces that Teijin Limited has resolved to establish a new subsidiary, Teijin Regenet Co., Ltd., which will inherit the rights and obligations related to the regenerative medicine CDMO business, effective August 1, 2023. The new company will be a wholly-owned subsidiary of Teijin Limited, with a capital of 100 million yen, focusing on the regenerative medicine CDMO business. The purpose of this division is to enhance the flexibility of business strategies and promote future business development. There will be no changes to the name, location, representative, or capital of Teijin Limited after the division.